Rating History for Regenxbio Inc. (RGNX) by Barclays
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 8/7/2026 | Eliana Merle | Downgrade | Equalweight (Overweight) |
12.00 (N/A) |
10.50 (9.11) |
-13.24% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 8/7/2026 | Eliana Merle | Downgrade | Equalweight (Overweight) |
12.00 (N/A) |
10.50 (9.11) |
-13.24% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||